Denali Therapeutics (DNLI) Retained Earnings: 2017-2025
Historic Retained Earnings for Denali Therapeutics (DNLI) over the last 8 years, with Sep 2025 value amounting to -$1.9 billion.
- Denali Therapeutics' Retained Earnings fell 35.02% to -$1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 billion, marking a year-over-year decrease of 35.02%. This contributed to the annual value of -$1.5 billion for FY2024, which is 37.88% down from last year.
- As of Q3 2025, Denali Therapeutics' Retained Earnings stood at -$1.9 billion, which was down 7.07% from -$1.8 billion recorded in Q2 2025.
- Over the past 5 years, Denali Therapeutics' Retained Earnings peaked at -$424.5 million during Q1 2021, and registered a low of -$1.9 billion during Q3 2025.
- In the last 3 years, Denali Therapeutics' Retained Earnings had a median value of -$1.3 billion in 2024 and averaged -$1.4 billion.
- Examining YoY changes over the last 5 years, Denali Therapeutics' Retained Earnings showed a top increase of 12.00% in 2021 and a maximum decrease of 81.99% in 2021.
- Over the past 5 years, Denali Therapeutics' Retained Earnings (Quarterly) stood at -$645.0 million in 2021, then slumped by 50.54% to -$971.0 million in 2022, then dropped by 14.96% to -$1.1 billion in 2023, then crashed by 37.88% to -$1.5 billion in 2024, then plummeted by 35.02% to -$1.9 billion in 2025.
- Its last three reported values are -$1.9 billion in Q3 2025, -$1.8 billion for Q2 2025, and -$1.7 billion during Q1 2025.